ScreenerHero

BTAIBioXcel Therapeutics, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · bioxceltherapeutics.com
0.8038USD-2.85%Mkt Cap: 25.16M $P/E: —

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immu…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap25.16M $
Enterprise Value116.61M $
Revenue (TTM)742.00K $
Gross Profit478.00K $
Net Income (TTM)-69.90M $
Revenue/Share0.0330 USD
Last Price0.8038 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS09075P1057
Valuation
P/E (Trailing)—
P/E (Forward)-0.51
PEG—
EV/EBITDA-2.62
EV/Revenue157.15
P/S33.69
P/B-0.22
EPS (TTM)-2.50
EPS (Forward)-1.57
52W Range
0.73651% of range6.850
52W High6.850 USD
52W Low0.7365 USD
Profitability
Gross Margin74.45%
Oper. Margin-5600.55%
EBITDA Margin0.00%
Profit Margin-10887.38%
ROE73.22%
ROA-155.62%
Growth
Revenue Growth51.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-57.62M $
CapEx (TTM)—
FCF Margin-4278.37%
FCF Yield-126.16%
Net Debt91.61M $
Net Debt/EBITDA-2.06
Balance Sheet
Debt/Equity-1.15
Current Ratio0.21
Quick Ratio0.09
Book Value/Sh-3.6880 USD
Cash/Share0.4100 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:16
Split DateFeb 10, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.33 USD
Upside (mean)+2180.8%
Target Range5.000 USD – 38.00 USD
$5.000+2180.8% to mean$38.00
# Analysts3
Ownership
Shares Out.31.31M
Float25.18M
Insiders3.60%
Institutions25.99%
Short Interest
Short Ratio3.2d
Short % Float13.91%
Short % Out.13.65%
Shares Short4.21M
Short (prev mo.)3.66M
Technical
SMA 501.012 (-20.6%)
SMA 2001.415 (-43.2%)
Beta0.29
S&P 52W Chg18.16%
Avg Vol (30d)936.12K
Avg Vol (10d)1.21M
Technical Indicators
RSI (14)41.2
MACD-0.0174
MACD Signal-0.0224
MACD Hist.+0.0050
BB Upper1.113 USD
BB Middle0.8937 USD
BB Lower0.6746 USD
BB Width49.05%
ATR (14)0.1094 USD
Vol Ratio (20d)1.72x